No abstract

We have used site-directed spin labeling and pulsed electron paramagnetic resonance to resolve a controversy concerning the structure of the utrophin-actin complex, with implications for the pathophysiology of muscular dystrophy. Utrophin is a homolog of dystrophin, the defective protein in Duchenne and Becker muscular dystrophies, and therapeutic utrophin derivatives are currently being developed. Both proteins have a pair of N-terminal calponin homology (CH) domains that are important for actin binding. Although there is a crystal structure of the utrophin actin-binding domain, electron microscopy of the actin-bound complexes has produced two very different structural models, in which the CH domains are in open or closed conformations. We engineered a pair of labeling sites in the CH domains of utrophin and used dipolar electron-electron resonance to determine the distribution of interdomain distances with high resolution. We found that the two domains are flexibly connected in solution, indicating a dynamic equilibrium between two distinct open structures. Upon actin binding, the two domains become dramatically separated and ordered, indicating a transition to a single open and extended conformation. There is no trace of this open conformation of utrophin in the absence of actin, providing strong support for an induced-fit model of actin binding.pulsed EPR | spectroscopy | cryo-EM U trophin is a homolog protein of dystrophin that has shown high therapeutic promise for the treatment of muscular dystrophy (1). It is endogenously found in fetal or regenerating muscle but is replaced by dystrophin, the defective protein in Duchenne and Becker muscular dystrophies, as the muscle matures (2). Up-regulation of utrophin in mdx mice, which lack dystrophin, has been shown to rescue its dystrophic phenotype, improving muscle morphology and function (1, 3). The full-length protein is not required to improve dystrophic pathology in mdx mice; i.e., substantial internal truncations in utrophin can be tolerated (4). These internally truncated constructs for muscular dystrophy therapeutics support the importance of actin binding by the N-terminal portions of either dystrophin or utrophin (5). Utrophin (395 kD) and dystrophin (427 kD) both contain highly homologous N-terminal actin-binding domains (ABD1), consisting of a pair of calponin homology (CH) domains. Despite additional actin-binding regions identified in the central spectrin-type repeats (6), microutrophin constructs with high potential for clinical applications rely almost exclusively on the N-terminal CH domains for actin interaction (7,8). Therefore, understanding the structural interaction between utrophin CH domains and actin has become crucial for the rational development of therapeutic constructs.More generally, there is an urgent need for a structural blueprint of CH domain-actin complexes for the entire spectrin superfamily of actin-binding proteins (e.g., fimbrin and α-actinin), of which dystrophin and utrophin are members. The diversity of crystal structur...

Dystrophin is an actin-binding protein thought to stabilize cardiac and skeletal muscle cell membranes during contraction. Here, we investigated the contributions of each dystrophin domain to actin binding function. Cosedimentation assays and pyrene-actin fluorescence experiments confirmed that a fragment spanning two-thirds of the dystrophin molecule (from N-terminal ABD1 through ABD2) bound actin filaments with high affinity and protected filaments from forced depolymerization, but was less effective in both assays compared to full-length dystrophin. While a construct encoding the C-terminal third of dystrophin displayed no specific actin binding activity or competition with full-length dystrophin, our data show that it confers an unexpected regulation of actin binding by the N-terminal two-thirds of dystrophin when present in cis. Time-resolved phosphorescence anisotropy experiments demonstrated that the presence of the C-terminal third of dystrophin in cis also influences actin interaction in terms of restricting actin’s rotational amplitude. We propose that the C-terminal region of dystrophin allosterically stabilizes an optimal actin binding conformation of dystrophin.

We have used time-resolved phosphorescence anisotropy (TPA) of actin to evaluate domains of dystrophin and utrophin, with implications for gene therapy in muscular dystrophy. Dystrophin and its homolog utrophin bind to cytoskeletal actin to form mechanical linkages that prevent muscular damage. Because these proteins are too large for most gene therapy vectors, much effort is currently devoted to smaller constructs. We previously used TPA to show that dystrophin and utrophin both have a paradoxical effect on actin rotational dynamics -- restricting amplitude while increasing rate, thus increasing resilience, with utrophin more effective than dystrophin. Here we have evaluated individual domains of these proteins. We found that a “mini-dystrophin,” lacking one of the two actin-binding domains, is less effective than dystrophin in regulating actin dynamics, correlating with its moderate effectiveness in rescuing the dystrophic phenotype in mice. In contrast, we found that a “micro-utrophin,” with more extensive internal deletions, is as effective as full-length dystrophin in the regulation of actin dynamics. Each of utrophin’s actin-binding domains promotes resilience in actin, while dystrophin constructs require the presence of both actin-binding domains and the CT domain for full function. This work supports the use of a utrophin template for gene or protein therapy designs. Resilience of the actin-protein complex, measured by TPA, correlates remarkably well with previous reports of functional rescue by dystrophin and utrophin constructs in mdx mice. We propose the use of TPA as an in vitro method to aid in the design and testing of emerging gene therapy constructs.

CDP-6-deoxy-l-threo-d-glycero-4-hexulose-3-dehydrase (E 1 ), along with its reductase (E 3 ), catalyzes the unusual C-3 deoxygenation of CDP-6-deoxyl-threo-d-glycero-4-hexulose to form CDP-3,6-dideoxy-l-threo-d-glycero-4-hexulose in CDP-ascarylose biosynthesis [Chen et al. (1996), Biochemistry, 35, 16412-16420]. This dimeric [2Fe-2S] protein, cloned from the bacteria Yersinia pseudotuberculosis, is currently the only known example of an enzyme that uses a vitamin B 6 -derived pyridoxamine 5 0 -phosphate (PMP) cofactor to carry out one-electron chemistry [Agnihotri & Liu (2001), Bioorg. Chem. 29, 234-257]. It also exhibits a [2Fe-2S] cluster-binding motif (C-X 57 -C-X 1 -C-X 7 -C) which has not been observed previously [Agnihotri et al. (2004), Biochemistry, 43, 14265-14274] The recombinant 97.7 kDa dimer was crystallized in the trigonal space group P3 2 , with unit-cell parameters a = b = 97.37, c = 142.2 Å , = = 90, = 120 . A data set has been collected to 1.9 Å resolution. A full MAD data set was also collected at the iron absorption edge that diffracted to 2.0 Å .